Clinical Trial Update: Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing tunlametinib in combination therapy for KRAS-mutated unresectable locally advanced or metastatic non-small cell lung cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tunlametinib (tunlametinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING